Inovio Pharma (INO) Issues Encouraging Update on INO-3112 in Generating CD8+ T Cell Responses in HPV 16, 18 Patients
Tweet Send to a Friend
Inovio Pharma (NASDAQ: INO) announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
